|Elizabeth Goodwin||Evelyn Fox|
|VP IR &Corporate Communications+1 781 460 1784||Director Communications +31 6 53 591 999 email@example.com|
|Paul van der HorstDirector IR & BusinessDevelopment+31 6 53 725 199|
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.